Post Content

Before drug manufacturers ship vaccines to distributors they, along with the Food and Drug Administration (FDA), always test them to determine that they meet all safety and efficacy standards. As part of its quality assurance program, manufacturer Sanofi Pasteur, performs additional routine, ongoing tests of their flu vaccines to ensure that they continue to meet required specifications after they have been distributed health care providers.

This week, after performing these tests, Sanofi Pasteur notified Centers for Disease Control (CDC) and the FDA that the antigen content in a batch (known as a "lot") of syringes intended for children 6 months through 35 months of age distributed to providers in November, had dropped below a pre-specified limit making them slightly less potent.

Consequently, Sanofi Pasteur tested additional lots and found that three others also had an antigen content that had fallen below pre-specified limits. This means that doses from these four vaccine lots no longer meet the specifications for antigen content. Therefore, Sanofi is conducting a voluntary recall of these affected lots and has asked providers to return any vaccine they may have from these lots to the manufacturer.

The affected vaccine met all specifications at the time of release and both CDC and FDA have determined that there are no safety concerns for children who received this vaccine. Parents of children who received vaccines from the recalled lots do not need to take any action other than make sure their child receives their second dose if they have not already. There is NO need to revaccinate children who have received vaccine from these lots. The antigen content in the affected lots of vaccine is only slightly below the specification limit and experts expect it to still be effective against the H1N1 flu.

This drop in antigen content below the required specification only occurred in Sanofi Pasteur’s pediatric H1N1 monovalent vaccine in 0.25 mL pre-filled syringes. The same vaccine packaged in other forms, such as pre-filled syringes for older children and adults and multi-dose vials, continue to meet specifications.

For additional information please see CDC’s Questions and Answers related to the withdrawn vaccine at http://www.cdc.gov/h1n1flu/vaccination/syringes_qa.htm

We encourage all residents to utilize the comments section on this blog to engage with us and each other. While we cannot respond to every comment or question directly, we find them very helpful to understand your questions and concerns and plan for future posts.

Written By:


Communications Office

Recent Posts

Let’s Keep Workers Safe: Plan. Provide. Train. posted on Apr 28

Today is Workers’ Memorial Day — the international day to remember workers who were injured, disabled, made unwell, or who died on the job. In just a six-year-period, in Massachusetts, 356 workers died on the job (2008-2013). These workers were our family members, friends and neighbors   …Continue Reading Let’s Keep Workers Safe: Plan. Provide. Train.

Vegetable Makhanwala posted on Apr 26

Vegetable Makhanwala

Back by popular demand, Kinnari Chitalia, RD, LDN, CLC, a nutritionist at the Dorchester North WIC Program, shares this mouthwatering favorite! This is a popular traditional dish in the northern part of India.  Its name refers to a creamy dish mixed with vegetables and aromatic   …Continue Reading Vegetable Makhanwala

Weekly Flu Report, April 22, 2016 posted on Apr 22

Rates of flu-like illness ticked up slightly over the course of the past seven days, according to the latest weekly flu report. Flu vaccination opportunities are still available in your community – call your health care provider or local board of health, or visit a pharmacy   …Continue Reading Weekly Flu Report, April 22, 2016